Spyre Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Spyre Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2015 to Q3 2024.
  • Spyre Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$13.6M, a 37.4% increase year-over-year.
  • Spyre Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$21.6M, a 72.6% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$96.5M, a 11728% decline from 2022.
  • Spyre Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $830K.
  • Spyre Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$11K, a 102% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$21.6M -$13.6M +$8.15M +37.4% Jul 1, 2024 Sep 30, 2024 10-Q/A 2024-11-18
Q2 2024 -$29.8M $5.31M +$63.1M Apr 1, 2024 Jun 30, 2024 10-Q/A 2024-11-18
Q1 2024 -$92.9M $3.95M +$3.6M +1035% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-11-18
Q4 2023 -$96.5M -$17.3M -$17.7M -4374% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-11-18
Q3 2023 -$78.8M -$21.8M -$22.1M -7077% Jul 1, 2023 Sep 30, 2023 10-Q/A 2024-11-18
Q2 2023 -$56.8M -$57.8M -$57.9M -53153% Apr 1, 2023 Jun 30, 2023 10-Q/A 2024-11-18
Q1 2023 $1.17M $348K +$343K +6860% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-11-18
Q4 2022 $830K $404K +$385K +2026% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-11-18
Q3 2022 $445K $312K +$300K +2500% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $145K $109K +$142K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $3K $5K +$14K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$11K $19K -$43K -69.4% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-11-18
Q3 2021 $32K $12K -$78K -86.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $110K -$33K -$175K -123% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $285K -$9K -$303K -103% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $588K $62K -$352K -85% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 $940K $90K -$483K -84.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $1.42M $142K -$461K -76.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.88M $294K -$196K -40% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $2.08M $414K +$7K +1.72% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-08
Q3 2019 $2.07M $573K +$247K +75.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.83M $603K +$347K +136% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $1.48M $490K +$364K +289% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $1.12M $407K +$263K +183% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-18
Q3 2018 $852K $326K +$202K +163% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $650K $256K +$168K +191% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $482K $126K +$42K +50% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $440K $144K +$84K +140% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-24
Q3 2017 $356K $124K +$61K +96.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $295K $88K +$23K +35.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $272K $84K +$64K +320% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $208K $60K +$50K +500% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-07
Q3 2016 $158K $63K +$59K +1475% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $99K $65K +$60K +1200% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $39K $20K +$19K +1900% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $20K $10K Oct 1, 2015 Dec 31, 2015 10-K 2018-03-13
Q3 2015 $4K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $5K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $1K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.